Estudio Clínico PREMOM

Desarrollo y validación del test MaiRa Hemos llevado a cabo un estudio clínico prospectivo multicéntrico que ha permitido demostrar la sensibilidad y especificidad del ARN libre circulante en el cribado precoz de la preeclampsia.

ClinicalTrials.gov: NCT04990141 (finalizado)								

Study characteristics

14 participating hospitals

~9,600 pregnant women included

26,000 samples collected

Longitudinal design by trimester

Objectives
→ Development of a predictive model based on cfRNA
→ Identification of a molecular signature associated with preeclampsia

Result: development of MaiRa

A partir de este ensayo estudio se ha logrado:

This study has made possible the development of the first blood test for the early prediction of the risk of preeclampsia.

Validated pipeline

Innovation and intellectual property

  • Patented cfRNA molecular signature
  • Proprietary predictive algorithm
  • Optimised laboratory protocol

Scientific publication

Results published in:

cfRNA as a predictor of preeclampsia